Human granulocytic ehrlichiosis
Human granulocytic ehrlichiosis
复制标题
DOI：
10.1086/313948
复制
发表时间：
2000-08-01
影响因子：
11.8
通讯作者：
Dumler, JS
中科院分区：
文献类型：
--
作者：
Bakken, JS;Dumler, JS
人粒细胞埃里希体病是最近认识到的蜱传播的传染病，并且迄今为止在美国和欧洲已经确定了>600名患者。大多数患者在蜱暴露或蜱叮咬后4周内出现非特异性发热性疾病。严重疾病或死亡的风险随着年龄的增长和治疗的延迟而增加。常规实验室检查可能显示外周血中白色血细胞和血小板浓度降低以及肝转氨酶活性轻度升高。高度的怀疑是必要的，以达到及时的临床诊断。怀疑患有人粒细胞埃立克体病（HGE）的患者应在等待确证性实验室检测结果的同时接受四环素类抗生素治疗。
Human granulocytic ehrlichiosis is a recently recognized tick-borne infectious disease, and to date >600 patients have been identified in the United States and Europe. Most patients have presented with a non-specific febrile illness occurring within 4 weeks after tick exposure or tick bite. The risk for serious illness or death increases with advancing age and delayed onset of therapy. Routine laboratory testing may reveal reduced white blood cell and platelet concentrations and mildly elevated hepatic transaminase activity in peripheral blood. A high index of suspicion is necessary to arrive at a timely clinical diagnosis. Patients suspected of having human granulocytic ehrlichiosis (HGE) should be treated with a tetracycline-class antibiotic while awaiting the outcome of confirmatory laboratory testing.